Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis
Authors
Keywords
V-set and immunoglobulin domain-containing 4 (Vsig4), C-type lectin domain family, 4 member F (Clec4F), Concanavalin A, Hepatitis, Steatohepatitis, Methionine choline deficiency (MCD), Nanobodies (Nbs)
Journal
MOLECULAR IMAGING AND BIOLOGY
Volume 19, Issue 1, Pages 49-58
Publisher
Springer Nature
Online
2016-06-24
DOI
10.1007/s11307-016-0976-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunology in the liver — from homeostasis to disease
- (2016) Felix Heymann et al. Nature Reviews Gastroenterology & Hepatology
- Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells
- (2016) Charlotte L. Scott et al. Nature Communications
- Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis
- (2015) Marta B. Afonso et al. CLINICAL SCIENCE
- Monitoring liver macrophages using nanobodies targeting Vsig4: Concanavalin A induced acute hepatitis as paradigm
- (2015) Fang Zheng et al. IMMUNOBIOLOGY
- Mouse models of metabolic liver injury
- (2015) P Ramadori et al. LABORATORY ANIMALS
- The concanavalin A model of acute hepatitis in mice
- (2015) F Heymann et al. LABORATORY ANIMALS
- Tissue-based map of the human proteome
- (2015) M. Uhlen et al. SCIENCE
- Molecular Imaging with Macrophage CRIg-Targeting Nanobodies for Early and Preclinical Diagnosis in a Mouse Model of Rheumatoid Arthritis
- (2014) F. Zheng et al. JOURNAL OF NUCLEAR MEDICINE
- Nanobody: The “Magic Bullet” for Molecular Imaging?
- (2014) Rubel Chakravarty et al. Theranostics
- Camelid single-domain antibody-fragment engineering for (pre)clinicalin vivomolecular imaging applications: adjusting the bullet to its target
- (2013) Jens De Vos et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- SPECT Imaging of Joint Inflammation with Nanobodies Targeting the Macrophage Mannose Receptor in a Mouse Model for Rheumatoid Arthritis
- (2013) S. Put et al. JOURNAL OF NUCLEAR MEDICINE
- Nanobody-Based Targeting of the Macrophage Mannose Receptor for EffectiveIn VivoImaging of Tumor-Associated Macrophages
- (2012) Kiavash Movahedi et al. CANCER RESEARCH
- Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions
- (2012) Alexis Broisat et al. CIRCULATION RESEARCH
- Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer
- (2012) Steve Schoonooghe et al. IMMUNOBIOLOGY
- Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer
- (2011) Ilse Vaneycken et al. FASEB JOURNAL
- Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice
- (2010) Lea Olive Tchouate Gainkam et al. Contrast Media & Molecular Imaging
- Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types
- (2010) K. De Groeve et al. JOURNAL OF NUCLEAR MEDICINE
- Antibody Vectors for Imaging
- (2010) Tove Olafsen et al. SEMINARS IN NUCLEAR MEDICINE
- General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold
- (2008) Cécile Vincke et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Latest Advances in Molecular Imaging Instrumentation
- (2008) B. J. Pichler et al. JOURNAL OF NUCLEAR MEDICINE
- Camelid immunoglobulins and nanobody technology
- (2008) S. Muyldermans et al. VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started